Issue Codes Incontinence Products for Women
People with overactive bladder could soon benefit from a new drug aimed at easing their night-time symptoms.
An overactive bladder is characterised by sudden urges to urinate that are difficult to ignore.
Patients often experience urge incontinence , in which they experience a need to urinate suddenly and are unable to reach a toilet in time.
For this reason, many patients with overactive bladder rely on incontinence products , such as Tena Lady .
Overactive bladder can also be problematic at night, when products such as Readi Washable Bed Pads (Kylies) may be required.
However, new clinical trial data involving a drug called Toviaz (fesoterodine fumarate) indicate that it may help to ease night-time urinary urgency and reduce people’s reliance on incontinence supplies .
Researchers tested the drug in a group of 937 patients in the US, all of whom took Toviaz or a placebo (dummy pill) during the 12-week trial.
They found that patients who took Toviaz for 12 weeks typically had far fewer episodes of night-time urinary urgency than those who used the placebo.
Dr Steven Romano, senior vice president of the Medicines Development Group at pharmaceutical company Pfizer, said: “Many patients with overactive bladder experience frequent interruptions during sleep hours from urinary urgency, which can be very disruptive and bothersome.
“In this study, Toviaz demonstrated efficacy in reducing the number of nocturnal urgency episodes.”
The findings suggest that Toviaz may be beneficial for people with overactive bladder.
Another treatment that could be effective is a new device that is implanted in the patient’s back and stimulates nerves at the base of the spine.
The technique – called permanent sacral nerve stimulation – is now being offered by NHS Greater Glasgow and Clyde and has been used in patients between the ages of 19 and 80.
The goal is to retrain the nerves controlling the bladder, thereby stopping the patient from leaking urine or emptying their bladder at the wrong time.
Issue Codes Incontinence Products for Women
People with overactive bladder could soon benefit from a new drug aimed at easing their night-time symptoms.
An overactive bladder is characterised by sudden urges to urinate that are difficult to ignore.
Patients often experience urge incontinence , in which they experience a need to urinate suddenly and are unable to reach a toilet in time.
For this reason, many patients with overactive bladder rely on incontinence products , such as Tena Lady .
Overactive bladder can also be problematic at night, when products such as Readi Washable Bed Pads (Kylies) may be required.
However, new clinical trial data involving a drug called Toviaz (fesoterodine fumarate) indicate that it may help to ease night-time urinary urgency and reduce people’s reliance on incontinence supplies .
Researchers tested the drug in a group of 937 patients in the US, all of whom took Toviaz or a placebo (dummy pill) during the 12-week trial.
They found that patients who took Toviaz for 12 weeks typically had far fewer episodes of night-time urinary urgency than those who used the placebo.
Dr Steven Romano, senior vice president of the Medicines Development Group at pharmaceutical company Pfizer, said: “Many patients with overactive bladder experience frequent interruptions during sleep hours from urinary urgency, which can be very disruptive and bothersome.
“In this study, Toviaz demonstrated efficacy in reducing the number of nocturnal urgency episodes.”
The findings suggest that Toviaz may be beneficial for people with overactive bladder.
Another treatment that could be effective is a new device that is implanted in the patient’s back and stimulates nerves at the base of the spine.
The technique – called permanent sacral nerve stimulation – is now being offered by NHS Greater Glasgow and Clyde and has been used in patients between the ages of 19 and 80.
The goal is to retrain the nerves controlling the bladder, thereby stopping the patient from leaking urine or emptying their bladder at the wrong time.